CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...
Phase 1, Phase 2
Salt Lake City, Utah, United States and 83 other locations
the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon...
Phase 2, Phase 3
Salt Lake City, Utah, United States and 827 other locations
does to the body besides treating the disease.Participants will have cancer that cannot be removed (unresectable) or has spread through the ...
Phase 1
Salt Lake City, Utah, United States and 7 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Phase 1
Salt Lake City, Utah, United States and 14 other locations
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal...
Phase 1, Phase 2
West Valley City, Utah, United States of America and 4 other locations
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, phar...
Phase 1
Salt Lake City, Utah, United States and 5 other locations
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors an...
Phase 2
Salt Lake City, Utah, United States and 79 other locations
Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus...
Phase 3
Salt Lake City, Utah, United States and 308 other locations
The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (pat...
Phase 2, Phase 3
Salt Lake City, Utah, United States and 42 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Salt Lake City, Utah, United States and 65 other locations
Clinical trials
Research sites
Resources
Legal